Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide plus ADT versus placebo plus ADT in metastatic hormone-sensitive prostate cancer
CTR20190132Phase 3Active
- Sponsor
- Astellas Pharma
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Started Sep 2019; status: active.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20190132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190132.